Clinical Trials Directory

Trials / Conditions / Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

8 registered clinical trials studyying Relapsed or Refractory Hodgkin Lymphoma — 3 currently recruiting.

StatusTrialSponsorPhase
CompletedReal-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed
NCT07145125
University Hospital, Bordeaux—
TerminatedPhase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
NCT05883449
Affimed GmbHPhase 2
RecruitingSHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT05896046
Chinese PLA General HospitalPhase 1 / Phase 2
Enrolling By InvitationAutologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After
NCT06931613
St. Petersburg State Pavlov Medical UniversityPhase 2
RecruitingPhase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
NCT03618550
Memorial Sloan Kettering Cancer CenterPhase 2
CompletedPilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lym
NCT01965119
Samsung Medical CenterPhase 2
CompletedA Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01572519
Janssen Research & Development, LLCPhase 1
CompletedStudy of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Ana
NCT01492088
Millennium Pharmaceuticals, Inc.Phase 1 / Phase 2